Celldex Therapeutics (CLDX) Stock
Celldex Therapeutics (CLDX) closed at $28.04 on Nov 17, 2026; its Tenet Score is 44 of 100 against 340 Healthcare peers.
30 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $28.04
- Nov 17, 2026
- Market cap
- $2.2B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 22.33 – 45.14
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 44/100
- Weak · 340 Healthcare peers
Industry: Drugs
Celldex Therapeutics Inc. scores 44/100. Weak. Strongest on financial health, growth is the soft spot versus 340 Healthcare peers.
Tenet Score · vs sector
n=340Factor grades
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Buffett Quality
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Quality Compounder
- ✕ Drawdown Context
- ✕ Reversal Evidence
13F flows & insider trades land here.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammator…
Similar-sized companies in Drugs
The 10 companies in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Arcus Biosciences IncRCUS | 31 | $2.4B |
| Neogen Corp.NEOG | 45 | $2.4B |
| Regencell Bioscience Holdings LtdRGC | 31 | $2.3B |
| NewAmsterdam Pharma Company NVNAMS | 58 | $2.3B |
| Lakefront Biotherapeutics NVLKFT | 82 | $2.3B |
| Perrigo Company plcPRGO | 40 | $2.3B |
| Beam Therapeutics IncBEAM | 61 | $2.2B |
| Immunome IncIMNM | 49 | $2.1B |
| Aurinia Pharmaceuticals IncAUPH | 82 | $2.1B |
| Schrodinger IncSDGR | 41 | $2.1B |
Common questions
What sector and industry is Celldex Therapeutics in?
Celldex Therapeutics is in the Healthcare sector and the Drugs industry.
What is Celldex Therapeutics' Tenet Score?
Celldex Therapeutics' Tenet Score is 44 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.




